Corium International Fund Company Profile

Description

Corium International, Inc., a biopharmaceutical company, focuses on the development, manufacture, and commercialization of specialty pharmaceutical products in transdermal and transmucosal delivery systems. It offers Clonidine Transdermal Delivery System (TDS), a treatment for hypertension; Fentanyl TDS, a treatment for the management of chronic pain, including cancer-related pain; Crest Whitestrips for teeth whitening. The company’s products under pipeline comprise AG200-15, a combination hormonal contraceptive patch, that is in phase III clinical trial to deliver ethinyl estradiol and levonorgestrel hormones; MicroCor hPTH(1-34), a transdermal system that has completed phase II a clinical trial for the treatment of osteoporosis; and Donepezil and Memantine transdermal systems, which are in phase I clinical trial for the treatment of Alzheimer's disease. In addition, it develops Aripiprazole TDS for the treatment for neurological disorders; Ropinirole TDS that is in preclinical stage for the treatment of Parkinson's disease; MicroCor Fentanyl for the treatment of breakthrough pain; MicroCor Zolmitriptan for treatment of migraine; generic transdermal product for the prevention of nausea and vomiting associated with motion sickness; and generic transdermal product for a urologic condition. Corium International, Inc. has collaboration agreements with The Procter & Gamble Company; Teva Pharmaceuticals USA, Inc.; Par Pharmaceutical, Inc.; Agile Therapeutics, Inc.; and others. The company was incorporated in 1995 and is headquartered in Menlo Park, California.